Effects of Germline CYP2W16 and CYP2B66 Single Nucleotide Polymorphisms on Mitotane Treatment in Adr...
Effects of Germline CYP2W16 and CYP2B66 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study
About this item
Full title
Author / Creator
Altieri, Barbara , Sbiera, Silviu , Herterich, Sabine , De Francia, Silvia , Della Casa, Silvia , Calabrese, Anna , Pontecorvi, Alfredo , Quinkler, Marcus , Kienitz, Tina , Mannelli, Massimo , Canu, Letizia , Angelousi, Anna , Chortis, Vasileios , Kroiss, Matthias , Terzolo, Massimo , Fassnacht, Martin and Ronchi, Cristina L
Publisher
Switzerland: MDPI
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI
More information
Scope and Contents
Contents
Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and no biomarkers are available to predict attainment of therapeutic plasma concentrations and clinical response. Aim of the study was to evaluate the suitability of cytochrome P450(CYP)2W1 and CYP2B6 single nucleotide polymorphisms (SNPs) as biomarkers. A multicenter co...
Alternative Titles
Full title
Effects of Germline CYP2W16 and CYP2B66 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7072643
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7072643
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers12020359
